Personalized Medical Care & Dedicated International Patient Concierge
Press Release
L&C Bio Launches 'Re2O PS-ABM' Composed of 11 Plastic Surgeons
L&C Bio has launched Re2O PS-ABM, an 11-member plastic surgeon advisory board setting clinical guidelines for Re2O and unveiling Re2O V. Learn more here.
Schedule a ConsultationL&C Bio Launches 'Re2O PS-ABM' Composed of 11 Plastic Surgeons

First Advisory Committee Meeting Held… Establishment of Standard Clinical Utilization Guidelines for Re2O
First Unveiling of 'Re2O V,' a New Product for Improving Skin Tissue Structure and Contours [The Bio Reporter Choi Seong-hun] L&C Bio, a company specializing in human tissue and human tissue-based medical devices, has officially launched the 'Re2O Plastic Surgery Advisory Board Member (hereinafter Re2O PS-ABM),' composed of 11 plastic surgeons.
L&C Bio announced on the 24th that it recently held the 1st Rituo PS-ABM at Andaz Seoul Gangnam and discussed actual clinical cases of Rituo, product-specific usage principles, standard evaluation items, and future research and academic publication directions.
Re2O PS-ABM is a specialized academic council established to objectively record and analyze experiences accumulated in the medical field and to develop them into reproducible clinical application guidelines and academic evidence. It was formed to systematize the clinical application of 'Re2O,' a human tissue-derived extracellular matrix (ECM) solution, in the field of plastic surgery.
Rituo PS-ABM promotes the establishment of standards for target subjects and sites of application, the development of standard usage methods based on skin and tissue conditions, the joint writing of clinical usage guidelines for each product, the standardization of case recording and evaluation methods, the review of post-procedure progress and safety, the establishment of a multi-center case registration system, and the publication of expert consensus, papers, and educational materials.
Rituo is based on acellular allogeneic dermal-derived ECM created by removing cellular components from donated human skin tissue. ECM is a key component that maintains the shape and structure of skin tissue and provides an environment for surrounding cells to settle.
Acellular allogeneic dermis, the base material of Re2O, has been used in the field of plastic surgery for over 30 years for the structural reinforcement and reconstruction of skin and soft tissues. It is a familiar human tissue material that plastic surgeons have encountered through various reconstructive surgeries since their residency training at university hospitals.
Through extensive experience, medical professionals have accumulated a deep understanding and trust regarding the physical properties, tissue application principles, efficacy, and safety of acellular allogeneic dermis. Based on this foundation, Rituo is being utilized in various clinical situations to supplement structural integrity in areas with insufficient or damaged ECM, and to restore skin structure and natural contours.
Eleven domestic plastic surgeons were appointed as advisory committee members for Rituo PS-ABM. At the first meeting, they presented major clinical cases utilizing Rituo and reviewed approaches based on the patient's skin condition and the anatomical characteristics of the application site, injection locations and ranges, and methods for observing and evaluating the progress after the procedure.
Various clinical cases were also shared, including skin atrophy and tissue defects, irregular contours resulting from surgery and trauma, scars, and areas requiring reconstruction. The advisory committee members reached a consensus on deriving common principles from the experiences of the medical staff and establishing standard criteria that can be utilized across various medical institutions.
At the event, 'Re2O V,' a new product scheduled for release in the second half of this year, was also introduced for the first time. Based on the structural characteristics of human dermal-derived ECM, Re2O V was developed to complement the structural integrity of skin tissue degraded by tissue defects or atrophy, and to restore a natural skin structure.
The advisory committee discussed appropriate application sites, targets, usage methods, evaluation criteria, and follow-up standards based on the physical properties of Re2O V. Moving forward, they plan to systematically collect relevant case studies to establish standard usage guidelines and expert consensus, and to develop these findings into academic presentations and research papers.
Lee Hyun-seung, Director of Marketing at L&C Bio, stated, “Acellular allogeneic dermis is a familiar and highly reliable material that plastic surgeons have used for skin and soft tissue reconstruction since their residency days at university hospitals.” He added, “We will objectively record and review the diverse experiences of medical professionals to develop reproducible clinical principles and academic evidence.” He further remarked, “We will expand academic exchanges with medical professionals both domestically and internationally and continuously accumulate scientific evidence for skin structure restoration and reconstruction using human-derived ECM.”
Source: THE BIO(https://www.thebionews.net)